uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
P/S ratio for uniQure N.V. (QURE)
P/S ratio as of 2023: 20.37
According to uniQure N.V.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 20.37. At the end of 2022 the company had a P/S ratio of 9.95.
P/S ratio history for uniQure N.V. from 2010 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 20.37 |
| 2022 | 9.95 |
| 2021 | 1.82 |
| 2020 | 42.83 |
| 2019 | 393.68 |
| 2018 | 91.03 |
| 2017 | 40.33 |
| 2016 | 5.59 |
| 2015 | 35.41 |
| 2014 | 44.51 |
| 2013 | 63.25 |
| 2012 | 0.00 |
| 2011 | 0.00 |
| 2010 | 0.00 |